BREAKING
Key metrics from Lowe’s (LOW) Q4 2025 earnings results 8 hours ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 1 day ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 1 day ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 1 day ago UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story 1 day ago Accenture plc (ACN) Drops 6.0% — Developing Story 1 day ago International Business Machines Corporation (IBM) Drops 9.4% — Developing Story 1 day ago Salesforce, Inc. (CRM) Surges 5.4% — Developing Story 1 day ago Advanced Micro Devices, Inc. (AMD) Surges 8.5% — Developing Story 1 day ago Salesforce, Inc. (CRM) Surges 5.4% — Developing Story 1 day ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 8 hours ago Earnings Preview: Best Buy (BBY) expected to report lower earnings in Q4 2026 1 day ago Apple Inc. (AAPL) Surges 5.1% — Developing Story 1 day ago Mastercard Incorporated (MA) Drops 5.6% — Developing Story 1 day ago UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story 1 day ago Accenture plc (ACN) Drops 6.0% — Developing Story 1 day ago International Business Machines Corporation (IBM) Drops 9.4% — Developing Story 1 day ago Salesforce, Inc. (CRM) Surges 5.4% — Developing Story 1 day ago Advanced Micro Devices, Inc. (AMD) Surges 8.5% — Developing Story 1 day ago Salesforce, Inc. (CRM) Surges 5.4% — Developing Story 1 day ago
ADVERTISEMENT
Earnings Transcript

Intuitive Surgical Q4 2025 Earnings Call Transcript

Advertisement

Corporate Participants

  • Gary Guthart – Chief Executive Officer
  • Jamie Samath – Chief Financial Officer
  • Brian King – Head of Investor Relations

Prepared Remarks

Brian King: Good afternoon, and welcome to Intuitive fourth quarter 2025 earnings call. With me are Gary Guthart, our CEO, and Jamie Samath, our CFO.

Gary Guthart: Intuitive delivered strong results with revenue of $2.1 billion and EPS of $1.84. da Vinci procedures grew 17% year-over-year globally, reflecting continued adoption across procedures and geographies.

We placed 493 da Vinci systems in the quarter, bringing our installed base to over 9,500 systems worldwide. Da Vinci 5 is seeing excellent adoption with its enhanced capabilities in visualization and instrumentation.

Our Ion platform for lung biopsy had 85 placements in Q4, bringing the installed base to over 700 systems. Early outcomes data continues to support strong clinical value.

Jamie Samath: Revenue of $2.1 billion reflected 15% growth year-over-year. Instruments and accessories revenue grew 18%, driven by procedure growth and favorable mix. Operating margin was 32%, up 150 basis points.

Q&A Session

Analyst: Can you provide an update on da Vinci 5 and customer feedback?

Gary Guthart: We are very pleased with da Vinci 5 reception. The system offers significant advances in visualization with the 3D high-definition display and enhanced force feedback. Early adopters report excellent outcomes and improved surgeon experience.

Analyst: What is your outlook for system placements in 2026?

Gary Guthart: We expect healthy system placement growth in 2026, driven by da Vinci 5 demand and geographic expansion. International markets, particularly China and Europe, represent significant growth opportunities.

Advertisement

Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, we cannot guarantee that all information is complete or error-free. Please refer to the company's official SEC filings for authoritative information.